pharmaphorum

JUNE 11, 2025

Skip to main content Wednesday 11 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Pharmaceutical Companies 87

Pharmaceutical Companies Pharmaceutical Companies Vaccines FDA 87

ISPE

SEPTEMBER 29, 2023

For more than 240 years, Takeda has focused on delivering transformative treatments in the therapeutic areas of gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Labelling Patient Care 52

European Pharmaceutical Review

OCTOBER 12, 2023

September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. The pharmaceutical company stated it will establish the first industrial-scale supply of biomethane. The Dunboyne facility is the company’s first biologics drug substance single-use commercialisation facility.

Vaccines 104

Vaccines Dosage Pharmaceutical Companies Pharmaceutical Companies 104

Pharmaceutical Technology

APRIL 24, 2023

Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures. As a result, some pharmaceutical companies are turning to third parties.

Vaccines 52

Vaccines Pharmaceutical Companies Pharmaceutical Companies Compounding 52

pharmaphorum

JANUARY 16, 2023

Rapid growth is forecasted from 2023 onwards: some industry observers predict that the global POC and rapid Dx market projected to reach $75bn by 2027, up from $45bn in 2022, at a CAGR of 10.7%. The fundamental engine of innovation for the global pharmaceutical industry continues. Innovation will power the market.

FDA 98

FDA Pharmaceutical Companies Pharmaceutical Companies Compounding 98

pharmaphorum

JANUARY 6, 2022

IQVIA Institute models global cumulative spend on COVID-19 vaccines to be a base case of $251bn to 2026 , with spend on COVID-19 treatments, including the new oral agents and treatments of post-viral syndromes, likely to add significant incremental spend. Medicine budget constraint, structural fund largesse.

Vaccines 111

Vaccines Pharmaceutical Companies Pharmaceutical Companies 111